The CVCA's February 2026 annual report puts Canadian venture capital at $8 billion across 571 deals in 2025. That number is technically accurate. It is also doing an enormous amount of work to hide a compression story that should worry anyone writing a seed-stage cheque in Vancouver right now.
The 26 Deals That Ate the Market
Strip out the 26 megadeals — rounds of $50 million or more — and the math gets uncomfortable fast. Those 26 transactions pulled in $5.3 billion, or 66% of all 2025 VC dollars, per CVCA data reported by BetaKit in February 2026. That leaves 545 deals splitting roughly $2.7 billion. Under $5 million average per deal. That is not a healthy early-stage market. That is a market where Series A and B rounds are getting quietly squeezed while a single firm — Toronto's Radical Ventures — raised $1.753 billion across two funds and statistically redefined what "Canadian VC fundraising" looks like in aggregate.
For context: historically, megadeal concentration in Canadian VC ran around 40 to 50 percent by dollar value through the 2018–2020 period. The 2021 boom temporarily masked the structural dependency by inflating deal counts across all stages. What 2025's 66% concentration actually reflects is a reversion — accelerated — to a market that was always propped up by a small number of anchor transactions. The CVCA's $8 billion figure is not wrong. It is strategically misleading in the same breath.
ICT Wins; Life Sciences and Cleantech Get Left Behind
ICT startups — the category that captures most AI companies — pulled in approximately $5 billion in 2025, close to 63% of all VC investment, according to CVCA data reported by The Logic. That concentration is real and not going away. US crossover funds with AI mandates are not going to start writing Series B cheques into Canadian biotech because a federal budget document asked nicely.
The sectors that bore the cost of that concentration:
- Life sciences VC dropped 47% year-over-year to $837 million in 2025, per CVCA via The Logic.
- Cleantech fell from roughly $1.2 billion in 2024 to $660 million in 2025, per the same CVCA annual report.
- Zero IPOs completed in Canada in 2025. Twenty-nine M&A exits total.
The life sciences collapse deserves more alarm than it's getting. Three years ago, the same "sector rotation into AI" framing was used to explain away biotech softness in the US — and it took 18 months before the honest read emerged: LP bases had simply repriced risk in anything with a 10-to-15-year development timeline. Canadian life sciences does not have the NIH backstop that US peers rely on. The enhanced SR&ED program — the CCPC expenditure limit raised to $6 million effective April 1, 2026, per the Government of Canada's Budget 2025 — improves the R&D incentive picture. But incentives do not replace equity capital when funds are chasing AI multiples.
Venture Debt at $1.4 Billion Is Not a Sophistication Story
The CVCA reported that venture debt hit a record $1.4 billion in 2025, with Q4 alone setting a quarterly record at $679 million. The coverage framed this as maturation of the Canadian market. That framing is wrong.
When founders are taking on non-dilutive debt at record rates in a zero-IPO, 29-M&A-exit environment, they are not optimizing their cap tables. They are buying time. The exit market is frozen. Capital recycling has effectively stopped. The LP base that would normally reinvest distributions into new Canadian funds is sitting on unrealized positions from 2021 and 2022 vintages that have not marked down honestly yet.
A senior partner at a Vancouver-based early-stage fund, who asked not to be named ahead of a live fundraise, put it plainly: "The debt numbers look like confidence. What they actually look like from inside a portfolio is founders extending runway because there is nowhere to go."
That debt reckoning is coming. Covenant deadlines will hit frozen exit conditions simultaneously in 2026 and 2027. Watch for that.
BC's $938M Ranking Conceals a Concentration Risk
British Columbia attracted $938 million in VC investment in 2025, ranking second nationally behind Ontario's approximately $2.6 billion, per the CVCA's Q3 2025 Market Overview. The provincial government has leaned into that number. BC's Budget 2025 raised the annual venture capital tax credit budget from $38.5 million to $53.5 million and increased the maximum individual investor tax credit from $120,000 to $300,000. Both moves are genuinely useful at the angel stage.
But angels writing $300,000 cheques do not solve a $5-to-$15-million gap-round problem. And BC's second-place national ranking is structurally more fragile than the dollar figure implies.
Ontario's $2.6 billion is anchored by Toronto's density of financial services infrastructure, US fund offices, and a university commercialization pipeline — MaRS, Waterloo — that BC does not replicate at scale. Vancouver's ecosystem is weighted toward enterprise software, gaming adjacencies, and resource-tech. It lacks the biotech cluster depth of Montreal or the fintech density of Toronto. InBC Investment Corp., the provincial government's VC arm, is sitting on a maturing legacy portfolio and has not signalled a dramatic deployment acceleration in its 2025–26 Service Plan. When the next sector rotation happens, BC's concentration risk is higher than its national ranking implies.
The Federal $1.75 Billion Bet and What It Can't Fix
Federal Budget 2025 commits $1 billion over three years to BDC Capital's new Venture and Growth Capital Catalyst Initiative — a fund-of-funds targeting pension and institutional co-investment — plus a further $750 million for early-growth-stage firms, with strategy details still to be announced in 2026, per the Department of Finance.
The intent is clear: reverse the collapse in domestic VC fundraising, pull pension capital off the sidelines, and give Canadian GPs the anchor commitments they need to lead deals rather than follow US funds. The 60% US investor participation rate in 2025 — the highest share since 2017, per CPE Analytics and RCG data from March 2026 — is the specific problem this policy is trying to address. When US parties lead or co-lead the majority of Canadian VC dollars, Canadian GPs build track records as syndicators, not lead investors. That affects their ability to raise independent funds from institutional LPs who want conviction-led deployment.
The honest counterpoint: the last time the federal government ran a major fund-of-funds intervention — the 2013 Venture Capital Action Plan — it took four years to show measurable impact on deal flow metrics. BDC's new mandate is better structured, but the question a skeptical LP committee would ask is whether the $1.75 billion is patient enough to wait for the 2028–2030 window when current portfolio companies actually need growth capital, or whether political pressure forces premature deployment into the same overvalued late-stage deals already crowding the market.
The CVCA's headline number says $8 billion. The structure underneath it says something different. Canada's VC market is bifurcating — 26 deals at the top, a squeezed middle, and a recycling problem that federal policy is about to spend $1.75 billion pretending is primarily a supply problem. Whether that bet lands will show up in the 2027 annual report. The founders trying to close a $10 million round in Vancouver right now do not have that long to wait.
